重症患者β内酰胺类抗生素治疗药物监测的研究现状  

Research status on the therapeutic drug monitoring of β-lactam antibiotics in critically ill patients

作　　者：郭玲[1] 罗雪梅[2] 梁培[2] 葛卫红[1,2] 

机构地区：[1]南京中医药大学中西医结合鼓楼临床医学院,南京210029 [2]南京大学医学院附属鼓楼医院药学部,南京210008

出　　处：《中国临床药理学杂志》2017年第13期1271-1275,共5页The Chinese Journal of Clinical Pharmacology

基　　金：南京药学会-常州四药医院药学科研基金资助项目(2015YX001)

摘　　要：由于重症患者生理病理情况的特殊性,药物在其体内的药代动力学/药效学(PK/PD)参数改变较大,难以预测。当β内酰胺类抗生素用于重症患者抗感染治疗时,若按照指南、说明书和经验用药的推荐剂量用药,常会出现剂量不足或药物不良反应等情况,治疗药物监测(TDM)是优化重症患者抗生素使用的重要手段之一。本文将对2010-2016年有关重症患者使用β内酰胺类抗生素进行抗感染治疗的情况及其TDM现状作一综述。Because of the particularity of physiological and pathological conditions of critically ill patients,the pharmacokinetic/pharmacodynamic（ PK/PD） parameters of the drug are changeable and unpredictable.Using β-lactam antibiotics for anti-infective treatment of critically ill patients in accordance with the guidelines,instructions and experience would always lead to the case of insufficient dose and adverse reactions.Therapeutic drug monitoring（ TDM） is one of the important effective methods to optimize the use of antibiotics in critically ill patients. This article reviews the studies related to β-lactam antibiotics for the anti-infective treatment of critically ill patients and the status of β-lactams TDM during 2010-2016.

关 键 词：Β内酰胺类 重症患者 治疗药物监测 

分 类 号：R978.1[医药卫生—药品]